P Mesenbrink
Overview
Explore the profile of P Mesenbrink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
357
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dunn R, Greenhouse J, James D, Ohlssen D, Mesenbrink P
Osteoarthritis Cartilage
. 2020 May;
28(8):1020-1029.
PMID: 32416218
Objective: This study constructs a risk score for patients' progression to end-stage knee osteoarthritis (OA) within 4 years. Design: The Osteoarthritis Initiative (OAI) was a longitudinal study of the onset...
2.
Reid I, Black D, Eastell R, Bucci-Rechtweg C, Su G, Hue T, et al.
J Clin Endocrinol Metab
. 2013 Jan;
98(2):557-63.
PMID: 23293335
Context: Annual infusions of zoledronic acid 5 mg over 3 years have been shown to reduce fracture incidence. There is now evidence that the effects of a single dose of...
3.
Wark J, Bensen W, Recknor C, Ryabitseva O, Chiodo 3rd J, Mesenbrink P, et al.
Osteoporos Int
. 2011 Feb;
23(2):503-12.
PMID: 21331467
Summary: Patients treated with intravenous zoledronic acid 5 mg for osteoporosis may experience post-dose influenza-like symptoms. Oral acetaminophen/paracetamol or ibuprofen administered 4 h post-infusion reduced the proportion of patients with...
4.
Colon-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, et al.
Osteoporos Int
. 2010 Dec;
22(8):2329-36.
PMID: 21153021
Unlabelled: Patients in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Recurrent Fracture Trial were assessed for evidence of delayed hip fracture healing. No association was...
5.
Reid I, Gamble G, Mesenbrink P, Lakatos P, Black D
J Clin Endocrinol Metab
. 2010 Jun;
95(9):4380-7.
PMID: 20554708
Context: Intravenous aminobisphosphonates often cause an acute-phase response (APR), but the precise components of this, its frequency, and the risk factors for its development have not been systematically studied. Objective:...
6.
Eastell R, Lang T, Boonen S, Cummings S, Delmas P, Cauley J, et al.
Osteoporos Int
. 2009 Oct;
21(7):1277-85.
PMID: 19802508
Unlabelled: Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased...
7.
Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L, et al.
Neurology
. 2004 Apr;
62(7):1199-201.
PMID: 15079026
The authors investigated neuropsychiatric symptoms in mild cognitive impairment (MCI) from baseline data of the Investigation in the Delay to Diagnosis of AD with Exelon (InDDEx) study (n = 1,010)....
8.
Sachdeo R, Beydoun A, Schachter S, Vazquez B, Schaul N, Mesenbrink P, et al.
Neurology
. 2001 Sep;
57(5):864-71.
PMID: 11552018
Objective: To evaluate the efficacy and safety of oxcarbazepine (OXC) as monotherapy for patients with uncontrolled partial seizures. Methods: A multicenter, double-blind, randomized, parallel-group, dose-controlled monotherapy trial compared OXC at...
9.
Beydoun A, Sachdeo R, Rosenfeld W, Krauss G, Sessler N, Mesenbrink P, et al.
Neurology
. 2000 Jul;
54(12):2245-51.
PMID: 10881247
Objective: To evaluate the safety and efficacy of oxcarbazepine (OXC) 2,400 mg/day versus OXC 300 mg/day monotherapy in patients with medically refractory partial epilepsy. Background: OXC is primarily metabolized by...
10.
Glauser T, Nigro M, Sachdeo R, Pasteris L, Weinstein S, Abou-Khalil B, et al.
Neurology
. 2000 Jul;
54(12):2237-44.
PMID: 10881246
Objective: To evaluate the safety and efficacy of oxcarbazepine (OXC) as adjunctive therapy in children with inadequately controlled partial seizures on one or two concomitant antiepileptic drugs (AEDs). Background: OXC...